In 2002 a 23-yr-old female giant panda (Ailuropoda melanoleuca) presented with left hind limb lameness presumably due to osteoarthritis. For the next five years, arthritic episodes were managed with the nonsteroidal anti-inflammatory drug (NSAID) carprofen at 2 mg/kg p.o. s.i.d., then reduced to 1 mg/kg p.o. s.i.d. and withdrawn. Radiographs revealed osteoarthritis in various joints and lumbar spondylosis. In 2007 glucosamine and chondroitin at 1.65 g p.o. b.i.d. and a polyunsaturated fatty acid at 1 capsule p.o. s.i.d. By 2008, arthritic episodes were becoming more difficult to successfully manage and higher doses and longer durations of treatment with carprofen were needed (2 mg/kg p.o. b.i.d.) and by August 2009 episodic treatment was no longer successful so the carprofen was continued indefinitely at 1 mg/kg p.o. s.i.d. In November 2009 carprofen was increased to 2 mg/kg p.o. b.i.d. An NMDA antagonist amantadine sulphate was trialed and after 10 days at 200 mg p.o. s.i.d. the clinical signs resolved. Since then it has been maintained on carprofen at 1 mg/kg p.o. b.i.d., amantadine sulphate 200 mg p.o. s.i.d. and the neutraceuticals as above with no further relapses of arthritic pain.